Janus Henderson Global Life Sciences Fund Class A

Janus Henderson Global Life Sciences Fund Class A

JFNAX
Janus Henderson Global Life Sciences Fund Class AUS flagNASDAQ
- -
USD
- -
- -
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChat
Sector
Financial Services
Industry
Asset Management - Global
Address
151 Detroit Street Denver CO United States of America 80206
IPO Date
Jul 6, 2009
Business
Janus Henderson Global Life Sciences Fund Class A (JFNAX) is an open-end mutual fund managed by Janus Henderson Investors that seeks long-term capital growth by investing primarily in equity securities of companies with a life sciences orientation, with at least 80% of net assets allocated to such holdings and at least 25% in the life sciences sector; the portfolio targets firms addressing unmet medical needs or enhancing health care system efficiency across subsectors including biotechnology, pharmaceuticals, health care services, and medical devices. The fund employs a fundamental, bottom-up stock-picking approach with a blend investment style focused on growth stocks of large-cap companies domiciled primarily in the United States (82%), supplemented by non-U.S. equities from Europe, the United Kingdom, Eurozone, Japan, and other regions, benchmarked against the MSCI World Health Care Index. Top holdings as of recent data include Eli Lilly and Co. (8.39%), AstraZeneca PLC (4.55%), Johnson & Johnson (4.54%), UnitedHealth Group Inc. (3.91%), and Abbott Laboratories (3.23%), representing 24.62% of the portfolio; the fund features a net expense ratio of 0.98%, a front-end load of 5.75%, and a minimum initial investment of $2,500, available for sale in the United States. Janus Henderson Investors, the fund's manager, originated from the 2017 merger of Janus Capital (founded 1969 in Denver, Colorado) and Henderson Global Investors (roots in 1934 in London), and operates globally with headquarters in London and Denver; the firm manages assets across equities, fixed income, multi-asset, and alternatives for individual, advisor, and institutional clients worldwide. Recent developments at Janus Henderson include the October 2024 acquisition of Victory Park Capital Advisors, a global private credit manager, enhancing private markets capabilities and complementing its $36.3 billion securitized assets under management; a June 2025 strategic partnership with Guardian to manage $45 billion in investment-grade public fixed income assets; and the 2023 acquisitions of Tabula Investment Management and NBK Capital Partners (rebranded Janus Henderson Investors Middle East Limited), expanding structured credit and private markets offerings.